Please check your internet connection and try again.
# Meftal-Spas
## Overview
Meftal-Spas is a combination drug containing **Mefenamic Acid** (250 mg), an NSAID with analgesic and anti-inflammatory properties, and **Dicyclomine Hydrochloride** (10 mg), an anticholinergic/antispasmodic agent.
## Primary Indications
Treatment of spasmodic dysmenorrhea (menstrual cramps) and gastrointestinal spasms.
## Adult Dosing
* **Standard Dose:** 1 tablet (250mg/10mg) orally 3–4 times daily.
* **Maximum Dose:** Do not exceed 4 tablets in 24 hours.
* **Duration:** Limit use to the shortest duration possible, typically not exceeding 3 days for menstrual pain.
## Pediatric Dosing
* **General Recommendation:** Generally not recommended for children under 12 years of age.
* **Adolescents (12+ years):** Same as adult dosing.
* *Note: Safety and efficacy profiles are not well-established in pediatric populations for this specific combination.*
## Dose Adjustments
* **Renal Impairment:** Avoid or strictly limit use in moderate-to-severe renal impairment (eGFR <30 mL/min).
* **Hepatic Impairment:** Use with caution; monitor for increased toxicity.
* **Elderly:** Use lowest effective dose for shortest duration; increased risk of anticholinergic side effects (e.g., urinary retention, confusion, constipation).
## Contraindications
* Hypersensitivity to Mefenamic Acid, Aspirin, or other NSAIDs.
* Active peptic ulceration or inflammatory bowel disease (ulcerative colitis, Crohn’s).
* History of GI bleeding or perforation related to NSAID use.
* Severe renal, hepatic, or cardiac failure.
* Obstructive uropathy or gastrointestinal atony (due to Dicyclomine).
* Third trimester of pregnancy.
## Adverse Effects
* **Common:** Dizziness, dry mouth, nausea, diarrhea, abdominal pain, and blurred vision.
* **Serious:** GI ulceration or hemorrhage, nephrotoxicity, cardiovascular events (MI/stroke risk), and severe skin reactions (SJS/TEN).
* **Anticholinergic effects:** Urinary retention, tachycardia, and blurred vision.
## Key Drug Interactions
* **Anticoagulants (e.g., Warfarin):** Increased risk of bleeding.
* **Other NSAIDs/Corticosteroids:** Increased risk of GI toxicity.
* **Antihypertensives/Diuretics:** Reduced efficacy; potential for increased renal impairment.
* **Anticholinergics:** Additive side effects; avoid concurrent use with other dry-mouth or sedative-inducing agents.
## Monitoring
* Monitor for signs of GI bleeding (black/tarry stools).
* Monitor renal function (BUN/Creatinine) and blood pressure during prolonged treatment.
* Monitor for symptoms of urinary retention in elderly patients.
## Clinical Pearls
* **Administration:** Take with food or milk to minimize gastric irritation.
* **Avoid prolonged use:** Due to the Mefenamic acid component, avoid chronic use to reduce the risk of cardiovascular and gastrointestinal events.
* **Anticholinergic Warning:** Dicyclomine may impair mental alertness; advise patients to use caution when driving or operating machinery.
* **Pregnancy:** Mefenamic acid can cause premature closure of the ductus arteriosus; strictly avoid in the third trimester.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug information is subject to change based on local regulations and updated clinical evidence. Always verify dosing, contraindications, and drug interactions against the most current local prescribing information, formulary guidelines, or a comprehensive pharmacology database (e.g., Lexicomp, UpToDate) before prescribing or administering.
